{"id":"https://openalex.org/W1985147573","doi":"https://doi.org/10.1001/archderm.144.6.779","title":"Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib","display_name":"Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib","publication_year":2008,"publication_date":"2008-06-01","ids":{"openalex":"https://openalex.org/W1985147573","doi":"https://doi.org/10.1001/archderm.144.6.779","mag":"1985147573","pmid":"https://pubmed.ncbi.nlm.nih.gov/18559769"},"language":"en","primary_location":{"id":"doi:10.1001/archderm.144.6.779","doi":"https://doi.org/10.1001/archderm.144.6.779","is_oa":false,"landing_page_url":"https://doi.org/10.1001/archderm.144.6.779","pdf_url":null,"source":{"id":"https://openalex.org/S115046667","display_name":"Archives of Dermatology","issn_l":"0003-987X","issn":["0003-987X","1538-3652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. dshong@mdanderson.org","Investigational Cancer Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. dshong@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Investigational Cancer Therapeutics","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029070588","display_name":"Srini Reddy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srini B. Reddy","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087156478","display_name":"Victor Gerardo Prieto","orcid":"https://orcid.org/0000-0001-9204-7161","observed_orcids":["https://orcid.org/0000-0001-9204-7161"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Victor G. Prieto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"John J. Wright","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John J. Wright","raw_affiliation_strings":["National Institutes of Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institutes of Health","institution_ids":["https://openalex.org/I1299303238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058115259","display_name":"Nizar M. Tannir","orcid":"https://orcid.org/0000-0001-5559-8060","observed_orcids":["https://orcid.org/0000-0001-5559-8060"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nizar M. Tannir","raw_affiliation_strings":["Genitourinary Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genitourinary Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103181930","display_name":"Philip R Cohen","orcid":"https://orcid.org/0000-0003-4772-2898","observed_orcids":["https://orcid.org/0000-0003-4772-2898"]},"institutions":[{"id":"https://openalex.org/I44461941","display_name":"University of Houston","ror":"https://ror.org/048sx0r50","country_code":"US","type":"education","lineage":["https://openalex.org/I44461941"]},{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip R. Cohen","raw_affiliation_strings":["University of Houston","University of Texas Health Science Center at Houston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Houston","institution_ids":["https://openalex.org/I44461941"]},{"raw_affiliation_string":"University of Texas Health Science Center at Houston","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026562050","display_name":"Abdul Hafeez Diwan","orcid":"https://orcid.org/0000-0001-6515-1828","observed_orcids":["https://orcid.org/0000-0001-6515-1828","https://orcid.org/0000-0003-3404-9497"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Hafeez Diwan","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019899650","display_name":"Harry L. Evans","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry L. Evans","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["University of Texas, M. D. Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas, M. D. Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":6.4326,"has_fulltext":false,"cited_by_count":53,"citation_normalized_percentile":{"value":0.96615722,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"144","issue":"6","first_page":"779","last_page":"82"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.8163999915122986,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.8163999915122986,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.17399999499320984,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.8009999990463257},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.7450000047683716},{"id":"https://openalex.org/keywords/tipifarnib","display_name":"tipifarnib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-induced-skin-cancer","display_name":"drug-induced skin cancer","score":0.7670000195503235},{"id":"https://openalex.org/keywords/cutaneous-adverse-effects","display_name":"cutaneous adverse events","score":0.5809999704360962},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.7900000214576721},{"id":"https://openalex.org/keywords/farnesyltransferase-inhibitors","display_name":"farnesyltransferase inhibitors","score":0.8880000114440918},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.9470000267028809},{"id":"https://openalex.org/keywords/keratoacanthoma","display_name":"keratoacanthoma","score":0.8939999938011169},{"id":"https://openalex.org/keywords/actinic-keratosis","display_name":"actinic keratosis","score":0.9369999766349792},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5870000123977661}],"concepts":[{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.965286135673523},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9074158668518066},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.47237542271614075},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46099451184272766},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4211551547050476},{"id":"https://openalex.org/C2777873816","wikidata":"https://www.wikidata.org/wiki/Q422225","display_name":"Actinic keratosis","level":3,"score":0.41314461827278137},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.41234228014945984},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.4070134162902832},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38067126274108887},{"id":"https://openalex.org/C3019992690","wikidata":"https://www.wikidata.org/wiki/Q92767510","display_name":"Basal cell","level":2,"score":0.3484730124473572},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.17226237058639526}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001706","descriptor_name":"Biopsy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003937","descriptor_name":"Diagnosis, Differential","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1001/archderm.144.6.779","doi":"https://doi.org/10.1001/archderm.144.6.779","is_oa":false,"landing_page_url":"https://doi.org/10.1001/archderm.144.6.779","pdf_url":null,"source":{"id":"https://openalex.org/S115046667","display_name":"Archives of Dermatology","issn_l":"0003-987X","issn":["0003-987X","1538-3652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of Dermatology","raw_type":"journal-article"},{"id":"pmid:18559769","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18559769","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of dermatology","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[{"id":"https://openalex.org/G3929822807","display_name":null,"funder_award_id":"5 UO1 CA062461","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8195082141","display_name":null,"funder_award_id":"TRI 25XS068","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"},{"id":"https://openalex.org/G8204861448","display_name":"Phase I Studies of Targeted Anti-Cancer Therapies","funder_award_id":"U01CA062461","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W204020518","https://openalex.org/W1491779959","https://openalex.org/W1975540542","https://openalex.org/W1985927918","https://openalex.org/W1992342802","https://openalex.org/W2048713916","https://openalex.org/W2075091190","https://openalex.org/W2109787198","https://openalex.org/W2112205129","https://openalex.org/W2133764101","https://openalex.org/W2140633731","https://openalex.org/W2144799273","https://openalex.org/W2153331460","https://openalex.org/W2167734044","https://openalex.org/W2172104048","https://openalex.org/W2183169576"],"related_works":["https://openalex.org/W99866307","https://openalex.org/W7098234375","https://openalex.org/W1985193085","https://openalex.org/W91109932","https://openalex.org/W1982483374","https://openalex.org/W2092917054","https://openalex.org/W1947952562","https://openalex.org/W2074354102","https://openalex.org/W2527690344","https://openalex.org/W2059387680"],"abstract_inverted_index":{"BACKGROUND:":[0],"Keratoacanthomas,":[1],"as":[2,4,117],"well":[3],"an":[5],"actinic":[6],"keratosis":[7],"progressing":[8],"to":[9,27,111],"squamous":[10,94,162],"cell":[11,50,95,163],"cancer,":[12],"have":[13,109],"been":[14],"reported":[15],"in":[16,125,165],"patients":[17],"who":[18,52],"were":[19,99],"treated":[20,54],"with":[21,47,55],"sorafenib,":[22],"a":[23,43,56],"multikinase":[24],"inhibitor":[25],"known":[26],"suppress":[28],"the":[29,126,138,141,145,154,158,172],"actions":[30],"of":[31,58,69,128,140,147,153,161,174],"Raf":[32],"kinase":[33],"and":[34,60,101,119,144],"vascular":[35],"endothelial":[36],"growth":[37],"factor":[38],"receptor.":[39],"OBSERVATIONS:":[40],"We":[41],"describe":[42],"70-year-old":[44],"white":[45],"woman":[46],"metastatic":[48],"renal":[49],"carcinoma":[51],"was":[53,104,135],"combination":[57],"sorafenib":[59,118],"tipifarnib":[61],"(a":[62],"farnesyltransferase":[63],"inhibitor).":[64],"She":[65],"had":[66],"no":[67],"history":[68],"skin":[70,175],"cancer.":[71],"However,":[72],"within":[73],"3":[74,82],"months":[75],"after":[76],"starting":[77],"this":[78,166],"therapy,":[79],"she":[80],"developed":[81,110],"erythematous":[83],"nodules":[84],"on":[85],"her":[86],"legs.":[87],"Pathologic":[88],"examination":[89],"showed":[90],"deeply":[91],"invasive,":[92],"well-differentiated":[93],"carcinomas.":[96],"The":[97],"tumors":[98],"excised,":[100],"sorafenib-tipifarnib":[102],"treatment":[103],"discontinued.":[105],"No":[106],"new":[107],"lesions":[108],"date.":[112],"CONCLUSIONS:":[113],"Targeted":[114],"agents,":[115],"such":[116],"tipifarnib,":[120],"are":[121],"increasingly":[122],"being":[123],"used":[124],"management":[127],"visceral":[129],"malignant":[130],"neoplasms.":[131],"A":[132],"temporal":[133],"relationship":[134],"observed":[136],"between":[137],"initiation":[139],"targeted":[142],"treatments":[143],"emergence":[146],"these":[148],"cutaneous":[149],"cancers.":[150],"Further":[151],"study":[152],"mechanisms":[155],"responsible":[156],"for":[157],"rapid":[159],"appearance":[160],"cancers":[164],"setting":[167],"may":[168],"provide":[169],"insights":[170],"into":[171],"pathogenesis":[173],"tumors.":[176]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}